TW197441B - - Google Patents

Info

Publication number
TW197441B
TW197441B TW080104761A TW80104761A TW197441B TW 197441 B TW197441 B TW 197441B TW 080104761 A TW080104761 A TW 080104761A TW 80104761 A TW80104761 A TW 80104761A TW 197441 B TW197441 B TW 197441B
Authority
TW
Taiwan
Prior art keywords
aryl
alkyl
heteroaryl
hydrogen
pct
Prior art date
Application number
TW080104761A
Other languages
English (en)
Chinese (zh)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of TW197441B publication Critical patent/TW197441B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Filtering Materials (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
TW080104761A 1990-06-21 1991-06-20 TW197441B (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54156890A 1990-06-21 1990-06-21

Publications (1)

Publication Number Publication Date
TW197441B true TW197441B (enExample) 1993-01-01

Family

ID=24160139

Family Applications (1)

Application Number Title Priority Date Filing Date
TW080104761A TW197441B (enExample) 1990-06-21 1991-06-20

Country Status (21)

Country Link
US (1) US5393755A (enExample)
EP (1) EP0538332B1 (enExample)
JP (1) JPH0747589B2 (enExample)
KR (1) KR960004532B1 (enExample)
AT (1) ATE155786T1 (enExample)
AU (1) AU651607B2 (enExample)
CA (1) CA2085733C (enExample)
CZ (1) CZ281920B6 (enExample)
DE (1) DE69126980T2 (enExample)
FI (1) FI925731A0 (enExample)
HU (1) HUT65623A (enExample)
IE (1) IE912126A1 (enExample)
IL (1) IL98559A0 (enExample)
NO (1) NO924940L (enExample)
NZ (1) NZ238609A (enExample)
OA (1) OA09723A (enExample)
PL (1) PL169481B1 (enExample)
RU (1) RU2080322C1 (enExample)
TW (1) TW197441B (enExample)
WO (1) WO1991019717A1 (enExample)
ZA (1) ZA914727B (enExample)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI953981A7 (fi) * 1993-02-26 1995-08-24 Schering Corp 2-Bentsyyli-polysykliset guaniinijohdannaiset ja menetelmä niiden valmistamiseksi
US5929046A (en) * 1994-06-08 1999-07-27 Cancer Research Campaign Technology Limited Pyrimidine and purine derivatives and their use in treating tumour cells
US5661153A (en) * 1994-07-19 1997-08-26 Japan Energy Corporation 1-arylpyrimidine derivatives and pharmaceutical use thereof
ZA969888B (en) * 1995-11-28 1997-05-26 Schering Corp 2'-[[4'-halo-[1,1-biphenyl]-4-yl]methyl]-5'-methyl-spiro[cyclopentane-1,7'(8'H)-[3H]imidazo[2,1-b]purin]-4'(5'H)-ones
US5824683A (en) * 1995-11-28 1998-10-20 Schering Corporation 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
CA2238283C (en) 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US6410584B1 (en) * 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
ES2166270B1 (es) * 1999-07-27 2003-04-01 Almirall Prodesfarma Sa Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
EP1790652A1 (en) * 2001-08-28 2007-05-30 Schering Corporation Polycyclic guanine phosphodiesterase V inhibitors
JP4450365B2 (ja) * 2001-08-28 2010-04-14 シェーリング コーポレイション 多環式グアニンホスホジエステラーゼｖ阻害剤
CA2459161A1 (en) 2001-08-31 2003-03-13 The Rockefeller University Phosphodiesterase activity and regulation of phosphodiesterase 1b-mediated signaling in brain
EP1312363A1 (en) * 2001-09-28 2003-05-21 Pfizer Products Inc. Methods of treatment and kits comprising a growth hormone secretagogue
CN1585771A (zh) * 2001-11-09 2005-02-23 先灵公司 多环鸟嘌呤衍生物磷酸二酯酶v抑制剂
US7342884B2 (en) * 2002-03-13 2008-03-11 Harmonic, Inc. Method and apparatus for one directional communications in bidirectional communications channel
PT1509525E (pt) * 2002-05-31 2006-12-29 Schering Corp Processo para preparação de xantinas inibidoras da fosfodiesterase v e de seus precursores
SI1509525T1 (sl) 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
EP1648895B1 (en) * 2003-07-31 2007-05-30 Schering Corporation Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction
AU2004260758B2 (en) * 2003-08-01 2007-06-07 Nippon Soda Co., Ltd. Phenylazole compounds, production process, and antioxidants
TW200526664A (en) * 2003-11-21 2005-08-16 Schering Corp Phosphodiesterase V inhibitor formulation
WO2006104870A2 (en) * 2005-03-25 2006-10-05 Schering Corporation Methods of treating benign prostatic hyperplasia or lower urinary track symptoms by using pde 5 inhibitors
EP1888534B1 (en) 2005-06-06 2017-07-26 Intra-Cellular Therapies, Inc. Organic compounds
EP1919287A4 (en) * 2005-08-23 2010-04-28 Intra Cellular Therapies Inc ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY
WO2007055170A1 (ja) * 2005-11-09 2007-05-18 Tosoh Corporation パーフルオロアルキル基を有する核酸塩基類およびその製造方法
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
WO2007143705A2 (en) * 2006-06-06 2007-12-13 Intra-Cellular Therapies, Inc. Organic compounds
EP2081431B1 (en) * 2006-11-13 2013-01-16 Intra-Cellular Therapies, Inc. Organic compounds
EP2089034A4 (en) * 2006-12-05 2010-07-28 Intra Cellular Therapies Inc NEW USES
JP2010530427A (ja) 2007-06-21 2010-09-09 シェーリング コーポレイション 多環式グアニン誘導体およびその使用方法
PT2240490E (pt) 2007-12-06 2013-12-09 Takeda Pharmaceutical Compostos orgânicos
KR20100094551A (ko) 2007-12-06 2010-08-26 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
PE20110995A1 (es) * 2008-12-06 2012-02-06 Intra Cellular Therapies Inc DERIVADOS DE PIRROLO[3,4-e]PIRIMIDINA COMO INHIBIDORES DE PDE1
EP2358723B1 (en) * 2008-12-06 2015-05-13 Intra-Cellular Therapies, Inc. 4,5,7,8-tetrahydro-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors
SG171777A1 (en) 2008-12-06 2011-07-28 Intra Cellular Therapies Inc Organic compounds
US8697710B2 (en) 2008-12-06 2014-04-15 Intra-Cellular Therapies, Inc. Optionally substituted 3-amino-4-(thioxo or imino)-4,5-dihydro-2H-pyrazolo [3,4-d]pyrimidin-6(7H)-ones
WO2010065147A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
WO2010065149A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
US11464781B2 (en) 2009-02-25 2022-10-11 Intra-Cellular Therapies, Inc. PDE1 inhibitors for ophthalmic disorders
JP5765239B2 (ja) * 2009-03-13 2015-08-19 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物
US9468637B2 (en) 2009-05-13 2016-10-18 Intra-Cellular Therapies, Inc. Organic compounds
JP6166534B2 (ja) 2009-08-05 2017-07-19 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規調節タンパク質および阻害剤
US20110190192A1 (en) * 2009-12-15 2011-08-04 Cebix Inc. Methods for treating erectile dysfunction in patients with insulin-dependent diabetes
EP2575817A4 (en) 2010-05-31 2014-01-08 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
US9371327B2 (en) 2010-05-31 2016-06-21 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
EP2576551A4 (en) 2010-05-31 2014-04-16 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
JP6051210B2 (ja) 2011-06-10 2016-12-27 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
WO2014127331A1 (en) 2013-02-17 2014-08-21 Intra-Cellular Therapies, Inc. Novel uses
ES2871327T3 (es) 2013-03-15 2021-10-28 Intra Cellular Therapies Inc Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de enfermedades o trastornos de SNC o SNP
MX378194B (es) 2013-03-15 2025-03-10 Intra Cellular Therapies Inc Compuestos organicos.
WO2015106032A1 (en) 2014-01-08 2015-07-16 Intra-Cellular Therapies, Inc. Products and pharmaceutical compositions
ES2732442T3 (es) 2014-06-20 2019-11-22 Intra Cellular Therapies Inc Compuestos orgánicos
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
JP6591530B2 (ja) 2014-08-07 2019-10-16 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
CN107106563B (zh) 2014-09-17 2021-05-25 细胞内治疗公司 化合物和方法
CN107205999B (zh) 2014-12-06 2021-08-03 细胞内治疗公司 有机化合物
EP3226862B1 (en) 2014-12-06 2020-07-08 Intra-Cellular Therapies, Inc. Phosphodiesterase 2 (pde2) inhibitory compounds
JP2019510039A (ja) 2016-03-28 2019-04-11 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
WO2018049417A1 (en) 2016-09-12 2018-03-15 Intra-Cellular Therapies, Inc. Novel uses
KR102590848B1 (ko) 2016-12-28 2023-10-19 다트 뉴로사이언스, 엘엘씨 Pde2 억제제로서 치환된 피라졸로피리미디논 화합물
KR102794907B1 (ko) 2017-11-27 2025-04-14 다트 뉴로사이언스, 엘엘씨 Pde1 억제제로서의 치환된 푸라노피리미딘 화합물
EP3746081A4 (en) 2018-01-31 2021-10-27 Intra-Cellular Therapies, Inc. Novel uses
US12410175B2 (en) 2019-09-03 2025-09-09 Intra-Cellular Therapies, Inc. Compounds
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE863525A (fr) * 1977-02-14 1978-07-31 Bristol Myers Co Heterocyclopyrimidines
CA1095906A (en) * 1977-02-14 1981-02-17 Davis L. Temple, Jr. Heterocyclopyrimidines, compositions and therapeutic process
AU623755B2 (en) * 1989-03-29 1992-05-21 Merrell Pharmaceuticals Inc. Selective adenosine receptor compounds
US5064947A (en) * 1989-03-29 1991-11-12 Merrell Dow Pharmaceuticals Inc. Selective adenosine reseptor compounds
US5173492A (en) * 1989-09-14 1992-12-22 Kyowa Hakko Kogyo Co., Ltd. s-Triazolo(3,4-I)purine derivatives
CA2028235C (en) * 1989-10-20 1997-01-21 Fumio Suzuki Condensed purine derivatives

Also Published As

Publication number Publication date
NO924940D0 (no) 1992-12-18
ZA914727B (en) 1992-03-25
EP0538332B1 (en) 1997-07-23
JPH05508647A (ja) 1993-12-02
IL98559A0 (en) 1992-07-15
FI925731A7 (fi) 1992-12-17
AU651607B2 (en) 1994-07-28
NZ238609A (en) 1993-12-23
HUT65623A (en) 1994-07-28
AU8199291A (en) 1992-01-07
DE69126980T2 (de) 1998-01-08
CA2085733C (en) 1996-03-05
HU9204032D0 (en) 1993-03-29
ATE155786T1 (de) 1997-08-15
IE912126A1 (en) 1992-01-01
PL169481B1 (pl) 1996-07-31
CA2085733A1 (en) 1991-12-22
JPH0747589B2 (ja) 1995-05-24
CZ281920B6 (cs) 1997-04-16
PL297299A1 (enExample) 1992-07-13
OA09723A (en) 1993-08-30
US5393755A (en) 1995-02-28
DE69126980D1 (de) 1997-09-04
RU2080322C1 (ru) 1997-05-27
NO924940L (no) 1992-12-18
WO1991019717A1 (en) 1991-12-26
CZ374992A3 (en) 1993-10-13
KR960004532B1 (ko) 1996-04-06
EP0538332A1 (en) 1993-04-28
FI925731A0 (fi) 1992-12-17

Similar Documents

Publication Publication Date Title
TW197441B (enExample)
DE69919897D1 (en) 4-oxo-1,4-dihydro-3-chinolincarboxamide als antivirale mittel
ES2164666T3 (es) Compuestos plaguicidas de pirimidina.
ATE155133T1 (de) Piperazinderivate als 5-ht antagonisten
DE69327913D1 (de) 1,2,4-Oxadiazolyl-Phenoxyalkyl-isoxazole und ihre Anwendung als antivirale Mittel
ES2123756T3 (es) Derivados de piperazina.
DE69431471D1 (de) Amide derivate als 5-ht1a liganden
TW281673B (enExample)
DE69104475D1 (de) Harnstoffderivate, ihre herstellung und deren enthaltende arzneimittel.
DE69416311D1 (de) Verwendung von cephem-derivaten als antimetastatische mittel
ATE203533T1 (de) INDOLDERIVATE ALS PRODRUGS VON ß5-HT1-LIKEß REZEPTOR AGONISTEN
DE69403896D1 (de) 4-amino-2-(hetero)aryl-butanamide verwenbar als 5-ht1a-antagonisten
ATE119883T1 (de) Thioformamidderivate.
MX9704262A (es) Piridazinonas como antagonistas del receptor endotelial.